🧬Biologics / Biosimilars
Large molecule drugs produced from living cells — antibodies, proteins, and biosimilars that target diseases with high precision.
Market Cap$4.3T
1D+0.10%
Companies1,421
Public Cos188
SECTOR MARKET CAP
$4.3T+13296.8%ALL
TOP COMPANIES
| # | Company | Country | Valuation | Ticker |
|---|---|---|---|---|
| 1 |  | United States | $981.8B | LLY |
| 2 |  | United States | $551.8B | JNJ |
| 3 |  | United States | $400.1B | ABBV |
| 4 |  | Switzerland | $281.1B | NVS |
| 5 |  | United Kingdom | $272.3B | AZN |
| 6 |  | Denmark | $200.5B | NVO |
| 7 |  | United States | $184.5B | AMGN |
| 8 |  | United States | $142.6B | PFE |
| 9 |  | France | $98.4B | SNY |
| 10 |  | Japan | $76.5B | 4519.T |
| 11 |  | United States | $62.9B | REGN |
| 12 |  | Netherlands | $56.3B | ARGX |
| 13 |  | Belgium | $53.1B | UCB.VI |
| 14 |  | United States | $48.8B | TAK |
| 15 |  | China | $48.4B | 600276.SS |
| 16 |  | Switzerland | $43.3B | LONN.SW |
| 17 |  | Germany | $42.0B | BAYN.DE |
| 18 |  | South Korea | $39.0B | 207940.KS |
| 19 |  | Australia | $37.9B | CSL.AX |
| 20 |  | Austria | $36.7B | SDZNY |